A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer.

Autor: Ylitalo EB; Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden., Thysell E; Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden., Landfors M; Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden., Brattsand M; Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden., Jernberg E; Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden., Crnalic S; Department of Surgical and Perioperative Sciences, Orthopedics, Umeå University, Umeå, Sweden., Widmark A; Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden., Hultdin M; Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden., Bergh A; Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden., Degerman S; Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden.; Department of Clinical Microbiology, Umeå University, Umeå, Sweden., Wikström P; Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden. pernilla.wikstrom@umu.se.
Jazyk: angličtina
Zdroj: Clinical epigenetics [Clin Epigenetics] 2021 Jun 30; Vol. 13 (1), pp. 133. Date of Electronic Publication: 2021 Jun 30.
DOI: 10.1186/s13148-021-01119-0
Abstrakt: Background: Patients with metastatic prostate cancer (PC) are treated with androgen deprivation therapy (ADT) that initially reduces metastasis growth, but after some time lethal castration-resistant PC (CRPC) develops. A better understanding of the tumor biology in bone metastases is needed to guide further treatment developments. Subgroups of PC bone metastases based on transcriptome profiling have been previously identified by our research team, and specifically, heterogeneities related to androgen receptor (AR) activity have been described. Epigenetic alterations during PC progression remain elusive and this study aims to explore promoter gene methylation signatures in relation to gene expression and tumor AR activity.
Materials and Methods: Genome-wide promoter-associated CpG methylation signatures of a total of 94 tumor samples, including paired non-malignant and malignant primary tumor areas originating from radical prostatectomy samples (n = 12), and bone metastasis samples of separate patients with hormone-naive (n = 14), short-term castrated (n = 4) or CRPC (n = 52) disease were analyzed using the Infinium Methylation EPIC arrays, along with gene expression analysis by Illumina Bead Chip arrays (n = 90). AR activity was defined from expression levels of genes associated with canonical AR activity.
Results: Integrated epigenome and transcriptome analysis identified pronounced hypermethylation in malignant compared to non-malignant areas of localized prostate tumors. Metastases showed an overall hypomethylation in relation to primary PC, including CpGs in the AR promoter accompanied with induction of AR mRNA levels. We identified a Methylation Classifier for Androgen receptor activity (MCA) signature, which separated metastases into two clusters (MCA positive/negative) related to tumor characteristics and patient prognosis. The MCA positive metastases showed low methylation levels of genes associated with canonical AR signaling and patients had a more favorable prognosis after ADT. In contrast, MCA negative patients had low AR activity associated with hypermethylation of AR-associated genes, and a worse prognosis after ADT.
Conclusions: A promoter methylation signature classifies PC bone metastases into two groups and predicts tumor AR activity and patient prognosis after ADT. The explanation for the methylation diversities observed during PC progression and their biological and clinical relevance need further exploration.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje